Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
Hs578T
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "Hs578T" in MCE Product Catalog:
Cat. No.: HY-P99386
CAS No.: 1205533-60-3
Synonyms: MNRP-1685A
Target:
Research Areas:
Cat. No.: HY-P990552A
Synonyms: 108600
Research Areas:
ON 108600 (108600) is a CK2 (CK2α1: IC50 = 50 nM; CK2α2 = 5 nM), TNIK (IC50 = 5 nM) and DYRK (DYRK1A: IC50 = 16 nM; DYRK1B = 7 nM; DYRK2: = 28 nM). ON 108600 suppresses the growth of CD44high/CD24low breast cancer stem cell (BCSC) populations, induces G2/M arrest and apoptosis in triple negative breast cancer (TNBC) cells, and inhibits tubulin polymerization. ON 108600 can be used for the study of chemotherapy-resistant and metastatic TNBC .
Synonyms: 10,11-(Methylenedioxy)-20(R)-camptothecin
Target:
Research Areas:
(R)-FL118 (10,11-(Methylenedioxy)-20(R)-camptothecin) is the R-enantiomer of FL118 (HY-12486). (R)-FL118 shows anticancer activity .
Cat. No.: HY-159176
CAS No.: 2775428-94-7
Target:
Cat. No.: HY-172966
CAS No.: 360760-58-3
EG31 is an EGFR inhibitor. EG31 effectively inhibits the proliferation of triple-negative breast cancer (TNBC) cells (GI50 values of MDA-MB-231 and Hs578T cells are 498.90 nM and 740.73 nM, respectively) and induces apoptosis by inhibiting the EGFR signaling pathway. EG31 still maintains antiproliferative activity against 5-fluorouracil (5-FU)-resistant TNBC cells (GI50: 519.5 nM). EG31 can be used to study TNBC resistance .
Cat. No.: HY-155271
Target:
Research Areas:
hCAXII-IN-7 (compound 6e) is a hCA XII inhibitor. hCAXII-IN-7 has BBB permeability. hCAXII-IN-7 induces 786-0, SF-539 and HS 578 T cells apoptotic .
Cat. No.: HY-178274
Target:
Research Areas:
SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research .
Cat. No.: HY-162575
CAS No.: 128519-30-2
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy .
Cat. No.: HY-184706
CAS No.: 3126116-06-8
Research Areas:
SHN7 is a selective HDAC1/HDAC6 inhibitor, NQO1 substrate and ROS inducer, with an IC50 of 30 nM against HDAC1 and an IC50 of 10 nM against HDAC6. SHN7 inhibits STAT3 with a Kd of 8.9 μM. SHN7 arrests the cell cycle at the G2/M phase and induces Apoptosis. SHN7 exhibits anti-tumor effects in triple-negative breast cancer (TNBC) xenograft models. SHN7 can be used for the research of triple-negative breast cancer .
Cat. No.: HY-186045
Target:
Histone Methyltransferase Apoptosis DNA/RNA Synthesis ATP-binding cassette (ABC) transporters
Research Areas:
SKLB06489 is a selective and orally active inhibitor of type I PRMT enzymes, with IC50 values of 64.55 nM (PRMT1), 4.21 nM (PRMT6), and 51.27 nM (PRMT8). SKLB06489 inhibits cell proliferation, colony formation, DNA replication, and DNA damage repair in cancer cells. SKLB06489 induces G0/G1-phase cell cycle arrest and apoptosis in cancer cells. SKLB06489 enhances intracellular cholesterol efflux via ABCA1 and ABCG1 upregulation, disrupts cholesterol metabolic homeostasis, and suppresses tumor growth in subcutaneous xenograft models. SKLB06489 can be used for the research of triple-negative breast cancer (TNBC) .
Cat. No.: HY-184013
Target:
Research Areas:
SU0617 is a selective SMUG1 inhibitor with a human IC50 of 1.5 μM. SU0617 inhibits base excision repair activity of SMUG1, including excision of modified and damaged pyrimidines from DNA. SU0617 can be used for the research of breast cancer .
Cat. No.: HY-187215
CAS No.: 2514847-74-4
Research Areas:
G9a ligand-1 is a target protein ligand that targets G9a, and it can be used in PROTAC-related research, such as serving as the PROTAC target protein ligand for PROTAC G9a degrader-1 (HY-187214) .
Cat. No.: HY-187214
Research Areas:
PROTAC G9a degrader-1 is a selective and orally active G9a PROTAC degrader with a DC50 of 1.29 μM. PROTAC G9a degrader-1 inhibits the NF-κB signaling pathway, suppresses the proliferation and migration of cancer cells, promotes apoptosis and cell cycle arrest, and reduces the expression level of H3K9me2. In in vivo models, PROTAC G9a degrader-1 alleviates skin inflammation, reduces epidermal hyperplasia, and decreases Ki67 expression. PROTAC G9a degrader-1 can be used for the research of triple-negative breast cancer and psoriasis .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
